Revium Rx.

Revium Rx is a U.S.-based pre-clinical biopharmaceutical company focused on developing nano-medicine and lipid-based drug delivery platforms. Its pipeline includes programs aimed at hard-to-treat diseases such as antimicrobial resistance and solid tumors, with development activities centered on encapsulated therapeutics and controlled-release delivery.

2.26

— Revium Rx.
	%
Nano-medicine programs	70% Preclinical therapeutic candidates built on nano-liposomal and lipid-based delivery systems.
Vaccine and prophylactic platform	20% Lipid-based platform work intended to support prophylactic and vaccine applications.
Research and development services	10% Internal development, regulatory preparation, and manufacturing-readiness activities.

Revium Rx does not currently sell commercial products; its near-term counterparties are research collaborators,...

Research collaborators and licensorsprimary
Academic and technology-transfer partners that provide scientific rights, data, or platform access for candidate development.
Contract development and manufacturing providersprimary
Third-party labs and manufacturers that support formulation, preclinical testing, and GMP preparation.
Potential licensing partnerssecondary
Pharmaceutical or biotech partners that may fund, license, or co-develop programs after proof-of-concept.
Future end patientsemerging
Patients with unmet-needs indications such as antimicrobial resistance or solid tumors, if products are approved.

Revium Rx is incorporated in the United States and operates as a U.S.-based public biopharmaceutical company...

•United States is the corporate base and reporting jurisdiction
•Israel is relevant through subsidiary and research collaboration ties
•Development work depends on external labs and service providers
•No commercial revenue geography is disclosed because sales have not begun

The company’s stated priority is to advance its Nano-Mupirocin program toward initial clinical development while...

Advance Nano-Mupirocin toward clinical developmentshort-term

This is the most advanced disclosed program and the clearest path to generating value and external interest.

Resolve Nano-Candesartan rights and study timingshort-term

Program progress depends on clearing the scientific-report dispute and restarting the planned safety study.

Validate the LPLT platform with proof-of-concept datamedium-term

Positive study results would support platform credibility, patent strategy, and future partnering.

Revium Rx faces the typical risks of a preclinical biotech company: scientific failure, regulatory delay, and...

critical

Going-concern and financing risk

The company depends on external capital to fund R&D and may need to reduce or delay programs if financing is unavailable.

Scope: All development programs
Materiality: high

high

Nano-Candesartan contractual dispute

The planned safety study is on hold pending resolution of a scientific-report and option-exercise disagreement with Yissum.

Scope: Nano-Candesartan program
Materiality: high

high

Preclinical and regulatory failure

Early-stage drug candidates may not demonstrate safety, efficacy, or manufacturability needed for clinical advancement.

Scope: All pipeline candidates
Materiality: high

medium

LPLT study execution delay

The SARS-CoV-2 challenge study has not produced results, delaying proof-of-concept validation and patent strategy work.

Scope: LPLT platform
Materiality: medium

Research and development expense timing

R&D spending and operating loss

Going-concern assessment

Financial statement disclosures and liquidity analysis

Collaborator and license-related contingencies

Potential liabilities and program rights

Preclinical development asset valuation

Balance sheet carrying values

Revium Rx.

Going-concern and financing risk

Nano-Candesartan contractual dispute

Preclinical and regulatory failure

LPLT study execution delay

REVIVA PHARMACEUTICALS HOLDINGS, INC.

RenovoRx, Inc.

REGENEREX PHARMA, INC.

COLLEGIUM PHARMACEUTICAL, INC

Neuraxis, INC

Assertio Holdings, Inc.